<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557268</url>
  </required_header>
  <id_info>
    <org_study_id>17-2328</org_study_id>
    <nct_id>NCT03557268</nct_id>
  </id_info>
  <brief_title>Pubertal Blockade and Hormone Therapy in Transgender Youth</brief_title>
  <acronym>PUBErTY</acronym>
  <official_title>Effects of Pubertal Blockade and Hormone Therapy on Cardiometabolic Risk Markers in Transgender Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll female-to-male transgender youth who are and are not on a puberty&#xD;
      blocker (gonadotropin-releasing hormone analogue) at baseline and 1 and 12 months after&#xD;
      starting testosterone. The study will evaluate markers of cardiometabolic health including:&#xD;
      insulin sensitivity, laboratory markers, vascular health, body composition, activity/fitness,&#xD;
      mitochondrial function and the microbiome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be a total of 6 study visits: baseline A, baseline B, 1 month after starting&#xD;
      testosterone (visit A and B) and 12 months after starting testosterone (visit A and B). No&#xD;
      medications will be administered as a part of this study.&#xD;
&#xD;
      Visit A procedures: Physical Examination, Laboratory, and Oral Glucose Tolerance Test (OGTT)&#xD;
      visit.&#xD;
&#xD;
      This will be conducted at Childrens Hospital Colorado (CHCO) Clinical &amp; Translational&#xD;
      Research Centers (CTRC) facilities. Physical examination will include vital signs,&#xD;
      anthropometric measurements, and breast/pubic hair staging as applicable (some subjects may&#xD;
      have already undergone mastectomy/chest masculinizing surgery) by the PI. Subjects will fast&#xD;
      for 8 hours prior to blood draw. Fasting blood work will be obtained, followed by an oral&#xD;
      glucose load (75g glucola). Blood glucose and insulin concentrations will be drawn at&#xD;
      baseline and 30, 60, 90 and 120 minutes after glucola administration. Serum will be obtained&#xD;
      at baseline and 2 hours post-OGTT and used for bile acid and lipid metabolomic profile. The&#xD;
      following questionnaires will be administered: REDCap Health Questionnaire, PedsQLTM 4.0&#xD;
      generic core questionnaire, PROMIS Pediatric Anxiety Short Form, PROMIS Pediatric Depressive&#xD;
      Symptoms Short Form, Insomnia Severity Index, Morningness and Eveningness Scale. Participants&#xD;
      will be mailed or emailed the 3-day dietary log prior to the visit and return it at this&#xD;
      visit. They will be given a stool microbiome collection kit and urine collection kit to&#xD;
      return at visit B. The medical chart will be reviewed for relevant health information and&#xD;
      medications.&#xD;
&#xD;
      Part B: Vascular Imaging, MR-based imaging and spectroscopy, Exercise Capacity and&#xD;
      Dual-energy X-ray (DXA) visit.&#xD;
&#xD;
      This will be conducted at the University of Colorado Denver Energy Balance Core and UCD Brain&#xD;
      Imaging Center. The participant will be fasting for a minimum of 4 hours prior to the&#xD;
      beginning of the study visit. The investigators will perform the tests in the following&#xD;
      order:&#xD;
&#xD;
        1. Participants will return stool microbiome and urine collection kit.&#xD;
&#xD;
        2. Vascular imaging: carotid artery stiffness and intimal medial thickness and brachial&#xD;
           artery flow-mediated dilation&#xD;
&#xD;
        3. Magnetic Resonance (MR) based imaging and spectroscopy&#xD;
&#xD;
        4. Oxygen consumption (VO2) peak exercise test on a stationary bicycle.&#xD;
&#xD;
        5. Total body dual energy x-ray absorptiometry (DXA)&#xD;
&#xD;
        6. Participants will be provided with an accelerometer and actigraphy watch to wear for a&#xD;
           period of 7 days to measure level of habitual physical activity and sleep, respectively.&#xD;
           They will also be provided a handout with instructions and a sleep and activity diary to&#xD;
           be filled out each day during the 7 days of wear.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Actual">September 9, 2020</completion_date>
  <primary_completion_date type="Actual">September 9, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin sensitivity</measure>
    <time_frame>Baseline and 12 months after initiation of testosterone.</time_frame>
    <description>Assessed by the Matsuda index, calculated from a 2-hour oral glucose tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vascular Health</measure>
    <time_frame>Baseline and 12 months after initiation of testosterone.</time_frame>
    <description>Brachial artery flow-mediated dilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mitochondrial function</measure>
    <time_frame>Baseline and 12 months after initiation of testosterone.</time_frame>
    <description>Hepatic mitochondrial function as assessed by 31Phosphorus- Magnetic Resonance Spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VO2 peak</measure>
    <time_frame>Baseline and 12 months after initiation of testosterone.</time_frame>
    <description>VO2 peak as measured on a bicycle ergometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body composition</measure>
    <time_frame>Baseline and 12 months after initiation of testosterone.</time_frame>
    <description>as measured on a Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>Gender Identity</condition>
  <condition>Gender Dysphoria</condition>
  <condition>Gender Identity Disorder in Adolescence and Adulthood</condition>
  <arm_group>
    <arm_group_label>On a GnRHa</arm_group_label>
    <description>Half of subjects will be on a puberty blocker or gonadotropin-releasing hormone analogue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Not on GnRHa</arm_group_label>
    <description>Half of subjects will NOT be on a puberty blocker or gonadotropin-releasing hormone analogue</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants will have the options of banking plasma, serum, urine and stool for future&#xD;
      research&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        16 female-to-male youth will be enrolled from 2 groups: 1) 8 female-to-male youth who have&#xD;
        been on a gonadotropin-releasing hormone analogue for &gt; 6 months; 2) 8 female-to-male&#xD;
        (age-matched) youth who never received gonadotropin-releasing hormone analogue therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Identify as female-to-male&#xD;
&#xD;
          -  Age 13-16 years at the time of enrollment&#xD;
&#xD;
          -  If on a gonadotropin-releasing hormone analogue, &gt; 6 months exposure&#xD;
&#xD;
          -  Plan to start testosterone clinically in &lt; 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the&#xD;
             study procedures&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Antipsychotic medication&#xD;
&#xD;
          -  Hypertension (resting BP â‰¥ 140/90 mm/Hg)&#xD;
&#xD;
          -  Weight &gt; 400 lbs (DXA and MRI limit)&#xD;
&#xD;
          -  On estrogen and/or progesterone medications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female-to-male transgender youth</gender_description>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Natalie J Nokoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gender Dysphoria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

